What is the safety of using Empagliflozin and Linagliptin in patients with Dilated Cardiomyopathy (DCM), Chronic Kidney Disease (CKD), and impaired renal function?

Empagliflozin + Linagliptin in Dilated Cardiomyopathy with Advanced CKD (Creatinine ~4)

Direct Recommendation

Empagliflozin should be initiated at 10 mg daily for cardiovascular and renal protection in this patient with dilated cardiomyopathy and advanced CKD, while linagliptin can be safely continued without dose adjustment. 1

---

Empagliflozin: Safety and Dosing in Advanced Renal Impairment

Renal Function Considerations

With a creatinine of ~4 mg/dL (corresponding to eGFR approximately 15-25 mL/min/1.73 m²), this patient falls into the severe CKD category where empagliflozin use requires careful consideration:

• Empagliflozin can be initiated if eGFR ≥20 mL/min/1.73 m² for cardiovascular and renal protection, even though glycemic efficacy is lost at this level of kidney function 1, 2
• The EMPA-KIDNEY trial specifically demonstrated efficacy in patients with eGFR as low as 20 mL/min/1.73 m², showing a 28% reduction in the composite outcome of kidney disease progression or cardiovascular death (HR 0.72,95% CI 0.64-0.82) 1, 2
• The dose remains fixed at 10 mg once daily regardless of eGFR level when used for cardiovascular/renal protection 1
• If eGFR falls below 20 mL/min/1.73 m² after initiation, empagliflozin 10 mg daily may be continued until dialysis is required 1

Cardiovascular Benefits in Dilated Cardiomyopathy

The rationale for using empagliflozin in this patient with DCM is particularly strong:

• Empagliflozin reduces heart failure hospitalization by 35% and cardiovascular death by 38% in patients with established cardiovascular disease 1
• In the EMPEROR-Preserved trial, empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% (HR 0.79,95% CI 0.69-0.90) 1
• Benefits are consistent regardless of diabetes status and across the spectrum of ejection fraction 1
• Empagliflozin carries a Class I recommendation for patients with heart failure to reduce cardiovascular death and hospitalization 3, 4

Renal Protection Despite Advanced CKD

• Empagliflozin reduced incident or worsening nephropathy by 39% and doubling of serum creatinine by 44% in the EMPA-REG OUTCOME trial 5
• The drug slows eGFR decline even in advanced CKD, with the EMPA-KIDNEY trial showing benefit in patients with baseline eGFR 20-45 mL/min/1.73 m² 1, 2
• An initial eGFR dip of 3-5 mL/min/1.73 m² within 1-4 weeks is expected and reversible—this should not prompt discontinuation 6

---

Linagliptin: Optimal DPP-4 Inhibitor for Advanced CKD

No Dose Adjustment Required

Linagliptin is the only DPP-4 inhibitor that requires no dose adjustment in any degree of renal impairment, including severe CKD and dialysis 1, 7:

• In patients with severe renal impairment (CrCl <30 mL/min), steady-state exposure increased by only 40%, which is not clinically significant 7
• Renal excretion accounts for <7% of elimination, with the majority (80%) eliminated via the enterohepatic system 7
• Continue linagliptin at standard 5 mg once daily dose without adjustment 7

Safety Profile in Heart Failure

The CARMELINA trial specifically addressed heart failure concerns with linagliptin:

• Linagliptin did NOT increase heart failure hospitalization risk (unlike saxagliptin which showed a 27% increase in SAVOR-TIMI 53) 1
• This makes linagliptin the preferred DPP-4 inhibitor in patients with established heart failure or at high risk for heart failure 1
• DPP-4 inhibitors can be used in renal impairment with dose adjustment, but linagliptin uniquely requires none 1

---

Critical Safety Monitoring and Precautions

Initial Monitoring Protocol

When initiating empagliflozin in this high-risk patient:

• Check eGFR and creatinine within 1-2 weeks after starting empagliflozin to assess for the expected initial dip 6
• Assess volume status before initiation and correct any volume depletion 6
• Consider reducing diuretic doses if patient is on loop diuretics to prevent excessive volume contraction 1, 3
• If eGFR decreases >30% from baseline AND there are signs of hypovolemia, reduce diuretics first before considering empagliflozin adjustment 6

Sick Day Management (Critical)

Empagliflozin must be held during acute illness to prevent diabetic ketoacidosis and volume depletion 6:

• Temporarily discontinue during fever, vomiting, diarrhea, or reduced oral intake 6
• Withhold at least 3 days before major surgery or procedures with prolonged fasting 6, 3
• Monitor for euglycemic DKA (can occur even with normal blood glucose) 6
• Resume only after recovery and normal oral intake is re-established 6

Adverse Effects to Monitor

• Genital mycotic infections occur in ~6% of patients on SGLT2 inhibitors (vs 1% on placebo)—counsel on hygiene measures 1, 6
• Volume depletion/hypotension risk is elevated in patients on diuretics, elderly, or with low baseline blood pressure 3
• Urinary tract infections are more common with SGLT2 inhibitors 1
• Rare but serious: Fournier's gangrene (necrotizing fasciitis of perineum)—requires immediate treatment if suspected 6

---

Drug Interaction Considerations

Empagliflozin-Linagliptin Combination

• No clinically significant pharmacokinetic interaction between empagliflozin and linagliptin 8
• The FDA label specifically states empagliflozin pharmacokinetics were similar with and without coadministration of linagliptin 8
• Low hypoglycemia risk with this combination as neither agent causes hypoglycemia independently 1, 6

Insulin/Sulfonylurea Adjustments

If patient is on insulin or sulfonylureas:

• Reduce total daily insulin dose by approximately 20% when starting empagliflozin if HbA1c is well-controlled 3, 4
• Consider weaning or stopping sulfonylureas to prevent hypoglycemia 3, 4

---

Clinical Decision Algorithm

For this patient with DCM, CKD, and creatinine ~4:

1. Calculate eGFR to confirm it is ≥20 mL/min/1.73 m²

   • If eGFR ≥20: Proceed with empagliflozin 10 mg daily 1, 2
   • If eGFR <20: Do NOT initiate empagliflozin; consider GLP-1 receptor agonist instead 1

2. Continue linagliptin 5 mg daily without dose adjustment 7

3. Assess volume status and adjust diuretics if needed before starting empagliflozin 6, 3

4. Monitor eGFR at 1-2 weeks, then every 3-6 months 6

5. Educate patient on sick day rules and when to hold empagliflozin 6

---

Common Pitfalls to Avoid

• Do NOT discontinue empagliflozin solely because eGFR falls below 45 mL/min/1.73 m²—cardiovascular and renal benefits persist even when glycemic efficacy is lost 1, 6
• Do NOT reduce linagliptin dose based on renal function—it requires no adjustment 7
• Do NOT panic about the initial eGFR dip—a 3-5 mL/min/1.73 m² decrease in the first 1-4 weeks is expected and actually predicts better long-term renal outcomes 6
• Do NOT use empagliflozin for glycemic control at this level of renal function—its benefit here is purely cardiovascular and renal protection 1

1, 6, 3, 4, 8, 7, 5, 2